Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1441-1461

  Dos Santos, Mariana Lopes ^a   Palanch, Carolina Gonçalves ^a   Salaorni, Sibeli ^a   Da Silva Jr , Wilson Araujo ^a   Nagai, Maria Aparecida ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; ERBB2; Gene expression; SAGE

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST; BREAST TUMOR; CELL LINE; CHROMOSOME MAP; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN CHROMOSOME; PHYSIOLOGY; PROTO ONCOGENE;

BREAST; BREAST NEOPLASMS; CELL LINE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN; FEMALE; GENE EXPRESSION REGULATION; GENES, ERBB-2; GENETIC MARKERS; HUMANS; RECEPTOR, ERBB-2; TRANSCRIPTION, GENETIC;

EID: 33747112128     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1441     Document Type: Article

References (60)

1. Holbro T, Civenni G and Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110, 2003.
2. Casalini P, Iorio MV, Galmozzi E and Menard S: Role of HER receptors family in development and differentiation. J Cell Physiol 200: 343-350, 2004.
3. Hung M-C and Lau Y-K: Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59, 1999.
4. Grant S, Qiao L and Dent P: Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 7: 376-389, 2002.
5. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
6. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
7. Slamon DJ, Godophin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
8. Ross JS and Fletcher JÁ: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428, 1998.
9. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1993.
10. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD and Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582, 1992.
11. Chen J-S, Lan K and Hung M-C: Strategies to target HER/neu overexpression for cancer therapy. Drug Resistance Updates 6: 129-136, 2003.
12. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Sleiger B and Kiessling R: Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108: 71-77, 2004.
13. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
14. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
15. Hulit J, Lee RJ, Russell RG and Pestell RG: ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochem Pharmacol 64: 827-836, 2002.
16. Barbacci EG, Pustilnik LR, Rossi AM, et al: The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res 63: 4450-4459, 2003.
17. Andrechek ER, Laing MA, Girgis-Gabardo AA, Siegel PM, Cardiff RD and Muller WJ: Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res 63: 4920-4926, 2003.
18. Oh JJ, Grosshans DR, Wong SG and Slamon DJ: Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 27: 4008-4017, 1999.
19. Wilson KS, Roberts H, Leek R, Harris AL and Gerardts J: Differential gene expression patterns in HER2/neu-positive and negative breast cancer cell lines and tissues. Am J Pathol 161: 1171-1185, 2002.
20. Mackay A, Jones C, Dexter T, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688, 2003.
21. Kumar-Sinha C, Borie N, Ginester C, et al: Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63: 132-139, 2003.
22. Bertucci F, Borie N, Ginestier C, et al: Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 23: 2564-2575, 2004.
23. Harris RA, Eichholtz TJ, Hiles ID, Page MJ and O'Hare MJ: New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer 80: 477-484, 1999.
24. Stamps AC, Davies SC, Burman J and O'Hare MJ: Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 57: 865-874, 1994.
25. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
26. Velculescu VE, Zhang L, Vogeltein B and Kinzler KW: Serial analysis of gene expression. Science 270: 484-487, 1995.
27. Pusztai L, Esteva FJ, Cristofanilli M, Hung MC and Hortobagvi GN: Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat Rev 25: 271-277, 1999.
28. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
29. Zhou BP and Hung MC: Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 30: 38-48, 2003.
30. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
31. Brunet A, Park J, Tran H, Hu LS, Hemmings BA and Greenberg ME: Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21: 952-965, 2001.
32. Cowburn AS, Cadwallader KA, Reed BJ, Farahi N and Chilvers ER: Role of PI3-kinase-dependent Bad phosphorylation and altered transcription in cytokine-mediated neutrophil survival. Blood 100: 2607-2616, 2002.
33. Fink AL: Chaperone-mediated protein folding. Physiol Rev 79: 425-449, 1999.
34. Soti C and Csermely P: Molecular chaperones in the etiology and therapy of cancer. Pathol Oncol Res 4: 316-321, 1998.
35. Pratt WB: The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 217: 420-434, 1998.
36. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43, 1999.
37. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L and Liu ZG: Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 275: 10519-10526, 2000.
38. Fortugno P, Beltrami E, Plescia J, Pradhan D, Marchisio PC, Sessa WC and Altieri DC: Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 100: 13791-13796, 2003.
39. Zhang R, Luo D, Miao R, Bai L, Ge Q, Sessa WC and Min W: Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24: 3954-3963, 2005.
40. Basso AD, Solit DB, Munster PN and Rosen N: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21: 1159-1166, 2002.
41. Xu W, Yuan X, Jung YJ, et al: The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 63: 7777-7784, 2003.
42. Wei YQ, Zhao X, Kariya Y, Teshigawara K and Uchida A: Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP) 70 expression in tumor cells. Cancer Immunol Immunother 40: 73-78, 1995.
43. Nylandsted J, Brand K and Jaattela M: Heat shock protein 70 is required for the survival of cancer cells. Ann NY Acad Sci 926: 122-125, 2000.
44. Wang G, Klostergaard J, Khodadadian M, et al: Murine cells transfected with human Hsp27 cDNA resist TNF-induced cytotoxicity. J Immunother Emphasis Tumor Immunol 19: 9-20, 1996.
45. Schepers H, Geugien M, van der Toorn M, Bryantsev AL, Kampinga HH, Eggen BJ and Vallenga E: HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 33: 660-670, 2005.
46. Schultheiss T, Lin ZX, Lu MH, et al: Differential distribution of subsets of myofibrillar proteins in cardiac nonstriated and striated myofibrils. J Cell Biol 110: 1159-1172, 1990.
47. Edlund M, Lotano MA and Otey CA: Dynamics of alpha-actinin in focal adhesions and stress fibers visualized with alpha-actinin-green fluorescent protein. Cell Motil Cytoskeleton 48: 190-200, 2001.
48. Otey CA, Vasquez GB, Burridge K and Erickson BW: Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. J Biol Chem 268: 21193-21197, 1993.
49. Miyamoto S, Teramoto H, Coso OA, Gutkind JS, Burbelo PD, Akiyama SK and Yamada KM: Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J Cell Biol 131: 791-805, 1995.
50. Bhatt A, Kaverina I, Otey C and Huttenlocher A: Regulation of focal complex composition and disassembly by the calcium-dependent protease calpain. J Cell Sci 115: 3415-3425, 2002.
51. Gluck U and Bem-Zeév A: Modulation of alpha-actinin levels affects cell motility and confers tumorigenicity on 3T3 cells. J Cell Sci 107: 1773-1782, 1994.
52. Hedjazifar S, Jenndahl LE, Shimokawa H and Baeckstrom D: PKB mediates c-erbB2-induced epithelial beta1 integrin conformational inactivation through Rho-independent F-actin rearrangements. Exp Cell Res 307: 259-275, 2005.
53. Ishikawa R, Yamashiro S and Matsumura F: Differential modulation of actin-severing activity of gelsolin by multiple isoforms of cultured rat cell tropomyosin. Potentiation of protective ability of tropomyosins by 83-kDa nonmuscle caldesmon. J Biol Chem 264: 7490-7497, 1989.
54. Pawlak G and Helfman DM: Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 11: 41-47, 2001.
55. Bhattacharya B, Prasad GL, Valverius EM, Salomon DS and Cooper HL: Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res 50: 2105-2112, 1990.
56. Cooper HL, Feuerstein N, Noda M and Bassin RH: Suppression of tropomyosin synthesis, a common biochemical feature of oncogenesis by structurally diverse retroviral oncogenes. Mol Cell Biol 5: 972-983, 1985.
57. Prasad GL, Fuldner RA and Cooper HL: Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci USA 90: 7039-7043, 1993.
58. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T and Prassad GL: Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 22: 6194-6203, 2003.
59. Mahadev K, Raval G, Bharadwaj S, et al: Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res 279: 40-51, 2002.
60. Feldner JC and Brandt BH: Cancer cell motility - on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 272: 93-108, 2002.